InnoCare Pharma Limited provided earnings guidance for the year ended 31 December 2023. Based on a preliminary estimate by the finance department, the net loss attributable to owners of the parent company in 2023 is expected to be approximately RMB 656 million, representing a decrease in loss of approximately 26% as compared with the corresponding period of the previous year. The net loss after excluding non-recurring gains or losses attributable to owners of the parent company was approximately RMB 654 million, representing a decrease of approximately 32% as compared with the corresponding period of the previous year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.1 HKD | +2.20% | -1.35% | -25.98% |
May. 16 | InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis | CI |
May. 14 | Innocare Pharma Posts Q1 Loss | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.98% | 1.25B | |
+8.84% | 114B | |
+11.47% | 104B | |
-12.75% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.14% | 17.89B | |
+8.33% | 14.28B | |
+34.89% | 12.55B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023